Visual Acuity in Aniridia and WAGR Syndrome

Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WA...

Full description

Saved in:
Bibliographic Details
Published inClinical ophthalmology (Auckland, N.Z.) Vol. 17; pp. 1255 - 1261
Main Authors Krause, Michael A, Trout, Kelly L, Lauderdale, James D, Netland, Peter A
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2023
Dove
Dove Medical Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses. The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects. Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.
AbstractList Purpose: Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. Materials and Methods: This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses. Results: The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95 [+ or -] 0.53 and 1.51 [+ or -] 0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78 [+ or -] 0.15 in aniridia subjects and 1.40 [+ or -] 0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects. Conclusion: Visual acuity was significantly worse in WAGR subjects with multi- gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome. Keywords: aniridia, WAGR syndrome, WAGR spectrum, PAX6, visual impairment, blindness
Michael A Krause,1 Kelly L Trout,2 James D Lauderdale,3 Peter A Netland1 1Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA; 2International WAGR Syndrome Association, Montgomery Village, MD, USA; 3Department of Cellular Biology, University of Georgia, Athens, GA, USACorrespondence: Peter A Netland, Department of Ophthalmology, University of Virginia School of Medicine, 1300 Jefferson Park Avenue, P.O. Box 800715, Charlottesville, VA, 22908-0715, USA, Tel +1 434-982-1086, Email pnetland@virginia.eduPurpose: Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.Materials and Methods: This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.Results: The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95± 0.53 and 1.51± 0.99, respectively (P< 0.001). In the better-seeing eye, mean LogMAR values were 0.78± 0.15 in aniridia subjects and 1.40± 0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.Conclusion: Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.Keywords: aniridia, WAGR syndrome, WAGR spectrum, PAX6, visual impairment, blindness
Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.PurposeOur purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.Materials and MethodsThis was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.ResultsThe age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.ConclusionVisual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.
Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses. The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects. Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.
Audience Academic
Author Lauderdale, James D
Trout, Kelly L
Netland, Peter A
Krause, Michael A
Author_xml – sequence: 1
  givenname: Michael A
  surname: Krause
  fullname: Krause, Michael A
– sequence: 2
  givenname: Kelly L
  surname: Trout
  fullname: Trout, Kelly L
– sequence: 3
  givenname: James D
  surname: Lauderdale
  fullname: Lauderdale, James D
– sequence: 4
  givenname: Peter A
  orcidid: 0000-0002-9523-2650
  surname: Netland
  fullname: Netland, Peter A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37152637$$D View this record in MEDLINE/PubMed
BookMark eNptkstr3DAQxkVJaB7trediKJRAuls9LEs-FROaBwRSmqU9ClmPXQVbSiW7sP995O6m7Iagg8Tom5_m08wJOPDBGwA-IDjHqGRf734sruf3JaQQkjfgGCHGZrTk5GDnfAROUnqAsMKQs7fgiDBEcUXYMTj_5dIou6JRoxvWhfNF41102slCel38bq5-Fvdrr2PozTtwaGWXzPvtfgoWl98XF9ez27urm4vmdqZoWQ8zUnEuNSElpcjmpesa8hoayyFvJSTWcqoxqiAxLcTISs2trTllkKhSUXIKbjZYHeSDeIyul3EtgnTiXyDEpZBxcKozAhPNNTUKY8XK7LaFFmvacmVqVLWGZNa3DetxbHujlfFDlN0edP_Gu5VYhr8CQZQ_q56qOdsSYvgzmjSI3iVluk56E8YkMEcom6n49NinjXQpc23O25CRapKLhlFWVlXJeFbNX1HlpU3vVO6tdTm-l_B5J2FlZDesUujGwQWf9oUfd83-d_nc7SzAG4GKIaVorFBukBMnl-C6bFpMIyWmkRLbkcpJX14kPXNflT8BrfTH-A
CitedBy_id crossref_primary_10_1007_s11596_024_2903_1
crossref_primary_10_1016_j_jtos_2023_05_010
Cites_doi 10.1016/j.preteyeres.2022.101133
10.1111/j.1755-3768.1980.tb08291.x
10.1136/jmedgenet-2019-106172
10.1016/S0161-6420(02)01839-0
10.3390/genes10121050
10.1038/ejhg.2012.100
10.2147/OPTH.S217930
10.1167/iovs.08-2827
10.1172/jci.insight.148406
10.1016/S0161-6420(13)38011-7
10.1016/j.ajo.2021.12.007
10.3928/1081-597X-19970701-16
10.3389/fped.2021.733018
10.1016/j.ophtha.2008.10.018
10.1186/s12886-022-02460-5
10.1016/j.survophthal.2021.02.011
10.3109/09286586.2015.1066394
10.1111/cge.12708
10.1056/NEJMoa054481
10.1016/j.ajo.2022.11.003
10.1542/peds.61.4.604
10.1542/peds.2004-0467
ContentType Journal Article
Copyright 2023 Krause et al.
COPYRIGHT 2023 Dove Medical Press Limited
2023 Krause et al. 2023 Krause et al.
Copyright_xml – notice: 2023 Krause et al.
– notice: COPYRIGHT 2023 Dove Medical Press Limited
– notice: 2023 Krause et al. 2023 Krause et al.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.2147/OPTH.S405003
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Krause et al
EISSN 1177-5483
EndPage 1261
ExternalDocumentID oai_doaj_org_article_23d8d5ec22c74117b0f2d5b8ce916be3
PMC10162095
A757466478
37152637
10_2147_OPTH_S405003
Genre Journal Article
GroupedDBID ---
0YH
29B
2WC
53G
5VS
6J9
7X7
8AO
8FI
8FJ
8G5
AAYXX
ABDBF
ABUWG
ACGFO
ACUHS
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
EBS
EJD
F5P
FRP
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HMCUK
HYE
IAO
IHR
IHW
ITC
KQ8
M2O
M48
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TDBHL
TR2
UKHRP
VDV
W2D
M~E
NPM
PMFND
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c549t-3688ad334551f1f1d990890ef808ba03ff85d21603eb021fad8ff985703c4c53
IEDL.DBID M48
ISSN 1177-5483
1177-5467
IngestDate Wed Aug 27 00:33:38 EDT 2025
Thu Aug 21 18:37:20 EDT 2025
Fri Jul 11 08:23:18 EDT 2025
Tue Jun 17 21:29:22 EDT 2025
Tue Jun 10 20:30:57 EDT 2025
Thu May 22 21:15:16 EDT 2025
Thu Jan 02 22:53:00 EST 2025
Thu Apr 24 22:58:54 EDT 2025
Tue Jul 01 02:21:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords visual impairment
PAX6
WAGR spectrum
WAGR syndrome
blindness
aniridia
Language English
License https://creativecommons.org/licenses/by-nc/3.0
2023 Krause et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c549t-3688ad334551f1f1d990890ef808ba03ff85d21603eb021fad8ff985703c4c53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9523-2650
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/OPTH.S405003
PMID 37152637
PQID 2811216683
PQPubID 23479
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_23d8d5ec22c74117b0f2d5b8ce916be3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10162095
proquest_miscellaneous_2811216683
gale_infotracmisc_A757466478
gale_infotracacademiconefile_A757466478
gale_healthsolutions_A757466478
pubmed_primary_37152637
crossref_citationtrail_10_2147_OPTH_S405003
crossref_primary_10_2147_OPTH_S405003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-01
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-01
  day: 01
PublicationDecade 2020
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
PublicationTitle Clinical ophthalmology (Auckland, N.Z.)
PublicationTitleAlternate Clin Ophthalmol
PublicationYear 2023
Publisher Dove Medical Press Limited
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Dove
– name: Dove Medical Press
References ref12
ref14
Bobilev (ref7) 2016
Riccardi (ref8) 1978; 61
ref16
Cunha (ref23) 2019; 10
Netland (ref2) 2011; 15
Rosenfeld (ref13) 2006; 355
Hingorani (ref19) 2009; 50
Alafaleq (ref25) 2023; 247
Hingorani (ref6) 2012; 20
Daruich (ref22) 2022
Shiple (ref5) 2015; 9
Vasilyeva (ref21) 2021; 58
Eckert (ref26) 2015; 22
Bajwa (ref4) 2019; 13
Holladay (ref18) 1997; 13
Jacobson (ref27) 2022; 22
Brown (ref24) 2006; 116
Hyvarinen (ref17) 1980; 58
Saaddine (ref15) 2003; 110
Kit (ref20) 2021; 6
(ref3) 2015
Fischbach (ref9) 2005; 116
Daruich (ref11) 2022; 237
Duffy (ref10) 2021; 9
Landsend (ref1) 2021; 66
References_xml – volume-title: Aniridia: Recent Developments in Scientific and Clinical Research
  year: 2015
  ident: ref3
– start-page: 101133
  year: 2022
  ident: ref22
  publication-title: Prog Retin Eye Res
  doi: 10.1016/j.preteyeres.2022.101133
– volume: 58
  start-page: 507
  year: 1980
  ident: ref17
  publication-title: Acta Ophthalmol
  doi: 10.1111/j.1755-3768.1980.tb08291.x
– volume: 58
  start-page: 270
  year: 2021
  ident: ref21
  publication-title: J Med Genet
  doi: 10.1136/jmedgenet-2019-106172
– volume: 110
  start-page: 253
  year: 2003
  ident: ref15
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(02)01839-0
– volume: 10
  start-page: 1050
  year: 2019
  ident: ref23
  publication-title: Genes
  doi: 10.3390/genes10121050
– volume: 9
  start-page: 291
  year: 2015
  ident: ref5
  publication-title: Clin Ophthalmol
– volume: 20
  start-page: 1011
  year: 2012
  ident: ref6
  publication-title: Eur J Hum Genet
  doi: 10.1038/ejhg.2012.100
– volume: 13
  start-page: 1469
  year: 2019
  ident: ref4
  publication-title: Clin Ophthalmol
  doi: 10.2147/OPTH.S217930
– volume: 50
  start-page: 2581
  year: 2009
  ident: ref19
  publication-title: Investig Ophthalmol Vis Sci
  doi: 10.1167/iovs.08-2827
– volume: 6
  start-page: 1
  year: 2021
  ident: ref20
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.148406
– ident: ref12
  doi: 10.1016/S0161-6420(13)38011-7
– volume: 237
  start-page: 122
  year: 2022
  ident: ref11
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2021.12.007
– volume: 13
  start-page: 388
  year: 1997
  ident: ref18
  publication-title: J Refractive Surg
  doi: 10.3928/1081-597X-19970701-16
– volume: 9
  start-page: 733018
  year: 2021
  ident: ref10
  publication-title: Front Pediatr
  doi: 10.3389/fped.2021.733018
– volume: 15
  start-page: 562
  year: 2011
  ident: ref2
  publication-title: JAAPOS
– volume: 116
  start-page: 57
  year: 2006
  ident: ref24
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2008.10.018
– volume: 22
  start-page: 235
  year: 2022
  ident: ref27
  publication-title: BMC Ophthalmol
  doi: 10.1186/s12886-022-02460-5
– volume: 66
  start-page: 1031
  year: 2021
  ident: ref1
  publication-title: Surv Ophthalmol
  doi: 10.1016/j.survophthal.2021.02.011
– volume: 22
  start-page: 349
  year: 2015
  ident: ref26
  publication-title: Ophthalmic Epidemiol
  doi: 10.3109/09286586.2015.1066394
– start-page: 1
  year: 2016
  ident: ref7
  publication-title: Clin Genet
  doi: 10.1111/cge.12708
– volume: 355
  start-page: 1419
  year: 2006
  ident: ref13
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa054481
– volume: 247
  start-page: 145
  year: 2023
  ident: ref25
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2022.11.003
– volume: 61
  start-page: 604
  year: 1978
  ident: ref8
  publication-title: Pediatrics
  doi: 10.1542/peds.61.4.604
– volume: 116
  start-page: 984
  year: 2005
  ident: ref9
  publication-title: Pediatrics
  doi: 10.1542/peds.2004-0467
– ident: ref16
– ident: ref14
SSID ssj0062087
Score 2.3039618
Snippet Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential...
Purpose: Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess...
Michael A Krause,1 Kelly L Trout,2 James D Lauderdale,3 Peter A Netland1 1Department of Ophthalmology, University of Virginia School of Medicine,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1255
SubjectTerms aniridia
Blindness
Comparative analysis
Diabetic retinopathy
Genetic aspects
Medical research
Medicine, Experimental
Original Research
pax6
visual impairment
wagr spectrum
wagr syndrome
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6TN1m7YOpOQQnNiSLc8eN6HJUsiDZJvkJmQ9iKF4S7L7_ztjaZc1IeRSfLPGIM3D80kef8PYji29H1lwma-MycoRiAyERiDHJdiy8Ca3fYHsmZz8Ln_dVrdrrb6oJizQAwfFHXBhwVbOcG4w-RV1k3tuqwaMQ2DTuJ7nE3PecjMV3sGS5xDbqtQZYnIRSt6pJ8_B-cV0sn-FOCVfNsqKyajn7H_8Zl5LTcOyybU8dPyGvY4AMh2Hib9lL1z3jr08jZ_I37O96_ZhQQJmgQA7bbt03LX3LbpBqjub3oxPLtOrSFPwgU2Pf06PJlnsiJAZ3MfNMyEBtBWiRJzj8bIj-myXOw85NDoX3kNlOXWOdg0mb68toCmIw16Y0lTiI9voZp37xFLptcHo04WzHjc9XFs5ghyxBT7BeSEStrfUjDKRLZyaVvxRuGsgPSrSo4p6TNiPlfTfwJLxhNwhKXklQ9zW_Q20uIoWV89ZPGHfyUQq_Ci6ilA1rquayPJrSNhuL0ExipM2Ov5qgEsntquB5NZAEmPLDIa3l26gaIgK0jo3WzwoDghUCykBp7MZ3GK1KlEjKJKiThgMHGaw7OFI19711N50loLuXH3-H4r6wl5xhGThwGiLbczvF-4rQqh5862Pln95vRTH
  priority: 102
  providerName: Directory of Open Access Journals
Title Visual Acuity in Aniridia and WAGR Syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/37152637
https://www.proquest.com/docview/2811216683
https://pubmed.ncbi.nlm.nih.gov/PMC10162095
https://doaj.org/article/23d8d5ec22c74117b0f2d5b8ce916be3
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEF9qC-KL-O1pPSMoPpTUZDfZnXsQuUrrIbSW9qrn05LshwZKTu8D9L93JtkLDVUkkIfsJOxOZjK_3Z38hrGXNvN-ZMHFPjcmzkYgYhAFAjkuwWapN4ltEmRP5OQi-zjLZ1tsU200KHD516kd1ZO6WFzu__r5-x06_FtKY04z9ebT6XSyf47Io6H93MGYpKiWwXHW7SdInkAos6JixOiiTYG_dncvODUc_te_1FdCVT-N8kpcOrrDbgdAGY1bC7jLtlx9j908Dlvm99ne52q5JgGzRsAdVXU0rqtFhWYRFbWNvow_nEXngbbgAZseHU7fT-JQISE2OK9bxUICFFaIDHGPx8OOaBsvcR4SKItEeA-55VRJ2pUYzH1hAV8NcdoLk5lcPGTb9bx2j1kkfWHQG4vUWY-TIF5YOYIEsQbewXkqBmxvoxltAns4FbG41DiLID1q0qMOehywV530j5Y14x9yB6TkToa4rpsL88U3HVxHc2HB5s5wbhD-pKpMPLd5CcYhtC0dPuQ5vSLd_jjaeaweq1wReb6CAXvdSJAVYadNEX49wKET-1VPcrcnib5mes0vNmagqYkS1Go3Xy81BwSuqZSA3XnUmkU3KqEQJEmhBgx6BtMbdr-lrr43VN-0tsIRBT_57xifslsc8Ve7OrTLtleLtXuGeGlVDtmN5OsEz2qmhmzn4PDk9GzYrD0MGyf5A5koE7U
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Visual+Acuity+in+Aniridia+and+WAGR+Syndrome&rft.jtitle=Clinical+ophthalmology+%28Auckland%2C+N.Z.%29&rft.au=Lauderdale%2C+James+D&rft.au=Krause%2C+Michael+A&rft.au=Netland%2C+Peter+A&rft.au=Trout%2C+Kelly+L&rft.date=2023-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1177-5483&rft.volume=17&rft.spage=1255&rft_id=info:doi/10.2147%2FOPTH.S405003&rft.externalDBID=n%2Fa&rft.externalDocID=A757466478
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1177-5483&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1177-5483&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1177-5483&client=summon